Display options
Cite
Zoratto F, Rossi L, Zullo A, et al. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther. 2012;5:199-211doi: 10.2147/OTT.S30581.
Zoratto, F., Rossi, L., Zullo, A., Papa, A., Zaccarelli, E., Tomao, L., Giordani, E., Colonna, M., Baiano, G., & Tomao, S. (2012). Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. OncoTargets and therapy, 5199-211. https://doi.org/10.2147/OTT.S30581
Zoratto, Federica, et al. "Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer." OncoTargets and therapy vol. 5 (2012): 199-211. doi: https://doi.org/10.2147/OTT.S30581
Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther. 2012;5:199-211. doi: 10.2147/OTT.S30581. Epub 2012 Sep 24. PMID: 23055745; PMCID: PMC3460673.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2012;5:199-211. doi: 10.2147/OTT.S30581. Epub 2012 Sep 24.

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer.

OncoTargets and therapy

Federica Zoratto, Luigi Rossi, Angelo Zullo, Anselmo Papa, Eleonora Zaccarelli, Luigi Tomao, Erika Giordani, Maria Colonna, Giovanni Baiano, Silverio Tomao

Affiliations

  1. Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University, Oncology Unit, "SM Goretti" Hospital, Latina.

PMID: 23055745 PMCID: PMC3460673 DOI: 10.2147/OTT.S30581

Abstract

Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metastatic colorectal cancer in recent years has increased from 5 months with best supportive care to nearly 2 years with chemotherapy combined with bevacizumab, an antivascular endothelial growth factor monoclonal antibody. New prognostic and predictive biomarkers have been identified to guide chemotherapy in metastatic colorectal cancer, such as KRAS and BRAF oncogenes. However, the status of these oncogenes does not affect the efficacy of bevacizumab, and biomarkers predicting response to treatment with bevacizumab are still lacking. Addition of bevacizumab to regimens based on fluoropyrimidines or irinotecan has been shown to improve overall survival in treatment-naïve patients with metastatic colorectal cancer. Similarly, a significant increase in overall survival rate is achieved by adding bevacizumab to fluoropyrimidines and oxaliplatin in patients with disease progression. Bevacizumab has been found to be effective even when used as third-line therapy and later. In addition, cohort studies have shown that bevacizumab improves survival significantly despite disease progression. Finally, bevacizumab therapy in the neoadjuvant setting for the treatment of liver metastasis is well tolerated, safe, and effective.

Keywords: bevacizumab; biomarkers; chemotherapy; liver metastases; metastatic colorectal cancer

References

  1. Int J Clin Oncol. 2012 Dec;17(6):604-9 - PubMed
  2. Am J Pathol. 2000 Apr;156(4):1363-80 - PubMed
  3. Oncology. 2010;78(5-6):376-81 - PubMed
  4. Int J Colorectal Dis. 2009 Jun;24(6):677-85 - PubMed
  5. J Clin Oncol. 2001 Feb 1;19(3):843-50 - PubMed
  6. Med Oncol. 2009;26(1):32-7 - PubMed
  7. J Mol Med (Berl). 1999 Jul;77(7):527-43 - PubMed
  8. Curr Opin Genet Dev. 2005 Feb;15(1):102-11 - PubMed
  9. Carcinogenesis. 2000 Mar;21(3):505-15 - PubMed
  10. J Clin Oncol. 2011 Jul 1;29(19):2675-82 - PubMed
  11. J Clin Oncol. 2005 Dec 20;23(36):9063-6 - PubMed
  12. Br J Cancer. 2009 Oct 6;101(7):1033-8 - PubMed
  13. Clin Cancer Res. 2007 Oct 1;13(19):5670-4 - PubMed
  14. Cancer Res. 1998 Mar 15;58(6):1149-58 - PubMed
  15. Ann Oncol. 2010 Jun;21(6):1152-1162 - PubMed
  16. N Engl J Med. 2006 Dec 14;355(24):2542-50 - PubMed
  17. Jpn J Clin Oncol. 2012 Feb;42(2):134-8 - PubMed
  18. J Clin Oncol. 2004 Jan 1;22(1):23-30 - PubMed
  19. N Engl J Med. 2004 Jun 3;350(23):2335-42 - PubMed
  20. J Pathol. 2004 Jan;202(1):5-13 - PubMed
  21. Ther Adv Med Oncol. 2012 Mar;4(2):75-89 - PubMed
  22. J Clin Oncol. 2007 Apr 20;25(12):1539-44 - PubMed
  23. Oncologist. 2009 Jan;14(1):22-8 - PubMed
  24. J Clin Oncol. 2009 Jan 10;27(2):199-205 - PubMed
  25. J Clin Oncol. 2010 Jul 10;28(20):3239-47 - PubMed
  26. J Clin Oncol. 2008 Jul 20;26(21):3523-9 - PubMed
  27. Oncologist. 2007 Mar;12(3):356-61 - PubMed
  28. Cancer. 2007 Dec 15;110(12):2761-7 - PubMed
  29. World J Gastroenterol. 2012 Mar 14;18(10):1104-9 - PubMed
  30. J Clin Oncol. 2010 Jul 1;28(19):3191-8 - PubMed
  31. J Clin Oncol. 2008 Apr 10;26(11):1830-5 - PubMed
  32. Nat Med. 1996 Sep;2(9):992-7 - PubMed
  33. Med Oncol. 2012 Dec;29(4):2842-8 - PubMed
  34. J Clin Oncol. 2007 Oct 20;25(30):4779-86 - PubMed
  35. J Clin Oncol. 2009 Feb 10;27(5):672-80 - PubMed
  36. J Clin Oncol. 2008 Nov 20;26(33):5344-51 - PubMed
  37. J Clin Oncol. 2007 Oct 10;25(29):4557-61 - PubMed
  38. Ann Oncol. 2011 Sep;22(9):2042-2048 - PubMed
  39. Oncology. 2009;77(2):113-9 - PubMed
  40. Nat Med. 2001 Nov;7(11):1194-201 - PubMed
  41. Ann Surg Oncol. 2010 Aug;17(8):2059-65 - PubMed
  42. BMC Cancer. 2009 Sep 28;9:347 - PubMed
  43. Cancer Res. 2002 Apr 1;62(7):1931-4 - PubMed
  44. Endocr Rev. 1997 Feb;18(1):4-25 - PubMed
  45. Br J Cancer. 2001 Aug 17;85(4):584-9 - PubMed
  46. Endocr Rev. 2004 Aug;25(4):581-611 - PubMed
  47. J Clin Oncol. 2010 Jan 20;28(3):453-9 - PubMed
  48. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  49. Oncologist. 2012;17(1):15-25 - PubMed
  50. Nature. 2002 Dec 19-26;420(6917):860-7 - PubMed
  51. Nature. 2004 Feb 19;427(6976):695 - PubMed
  52. Ann Surg Oncol. 2009 Jan;16(1):35-41 - PubMed
  53. J Cancer Res Clin Oncol. 2010 May;136(5):737-43 - PubMed
  54. BMC Cancer. 2012 Mar 13;12:89 - PubMed
  55. Cancer Res. 1997 Oct 15;57(20):4593-9 - PubMed
  56. J Clin Oncol. 2002 Nov 1;20(21):4368-80 - PubMed
  57. BMC Cancer. 2008 Apr 25;8:120 - PubMed
  58. Oncologist. 2000;5 Suppl 1:3-10 - PubMed
  59. J Clin Oncol. 2008 Nov 20;26(33):5326-34 - PubMed
  60. Ann Oncol. 2009 Nov;20(11):1842-7 - PubMed
  61. J Clin Oncol. 2003 Jan 1;21(1):60-5 - PubMed
  62. J Clin Oncol. 2008 Jan 20;26(3):374-9 - PubMed
  63. Lancet Oncol. 2010 Sep;11(9):845-52 - PubMed
  64. Cancer Invest. 2010 Jan;28(1):33-7 - PubMed
  65. EMBO J. 1989 Dec 1;8(12):3801-6 - PubMed
  66. J Clin Oncol. 2005 Jun 1;23(16):3697-705 - PubMed
  67. Clin Colorectal Cancer. 2012 Mar;11(1):38-44 - PubMed
  68. Nature. 2000 Sep 14;407(6801):249-57 - PubMed
  69. Clin Cancer Res. 2000 Sep;6(9):3739-47 - PubMed
  70. J Clin Oncol. 2006 Jul 20;24(21):3354-60 - PubMed
  71. N Engl J Med. 2009 Feb 5;360(6):563-72 - PubMed
  72. World J Gastroenterol. 2007 Dec 14;13(46):6231-5 - PubMed
  73. J Clin Oncol. 2008 Apr 20;26(12):2013-9 - PubMed
  74. Eur J Surg Oncol. 2009 May;35(5):515-20 - PubMed
  75. EMBO J. 1999 Jul 15;18(14):3964-72 - PubMed
  76. J Am Coll Surg. 2008 Jan;206(1):96-106 - PubMed
  77. J Natl Cancer Inst. 2005 Jul 6;97(13):981-9 - PubMed

Publication Types